Combining a MEKi with a BRAFi has shown enhanced efficacy in inhibiting tumor growth, delaying acquired resistance development, and eliminating paradoxical activation of the MAPK pathway in preclinical models of BRAF-mutated melanoma. Here, BRAF is linked to neoplasm.